Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
- Update frequency
- every 7 days
- Average duration
- 49 minutes
- Episodes
- 270
- Years Active
- 2020 - 2025
Resilient Biopharma Leadership With Ambrx's Dan O'Connor
We love to hear from our listeners. Send us a message.
Since Dan O'Connor stepped in as CEO at Ambrx late last year, the company's stock has rallied on the revival of a previously-shelved anti-HER2 A…
Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman
We love to hear from our listeners. Send us a message.
Like many of us, Howard Berman, Ph.D. has personal experience with the tragedy of cognitive decline. Neurodegenerative disorders are on the rise…
A More NIIMBL Biotech Workforce With John Balchunas
We love to hear from our listeners. Send us a message.
What are biopharma's greatest skilled manufacturing labor needs, and what's the industry doing to fill them? John Balchunas is on the front line…
Building Flagship Pioneering With Avak Kahvejian, Ph.D.
We love to hear from our listeners. Send us a message.
Flagship Pioneering is fertile ground for a bevy of blossoming biotechs, and one of its most prolific sowers is General Partner Avak Kahvejian, …
Therapeutic Molecules From Moss with eleva's Andreas Schaaf and Björn Cochlovius, Ph.D.
We love to hear from our listeners. Send us a message.
We kick this conversation off with the writer Elizabeth Gilbert's take on moss, which she so eloquenlty dubs a "resurrection engine." Gilbert al…
Gene Tx For Hearing Loss with Sensorion's Nawal Ouzren
We love to hear from our listeners. Send us a message.
We often talk about biotechs taking "big swings." This week's guest is swinging for the fences with a lineup of gene therapies designed to addre…
Functional Ectopic Organs with LyGenesis' Michael Hufford, Ph.D.
We love to hear from our listeners. Send us a message.
LyGenesis is developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organ…
Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.
We love to hear from our listeners. Send us a message.
Today's episode of the Business of Biotech covers a lot of ground with Enzyvant CEO Bill Symonds, Pharm.D. Among other things, we discuss the ca…
Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
We love to hear from our listeners. Send us a message.
The more we learn about inflammation and the complex cause/contributor/symptom roles it plays in various disease states, the more business activ…
Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
We love to hear from our listeners. Send us a message.
On the surface, the merger of Medsenic (a developer of arsenic salt formulations for therapeutic application in inflammatory conditions) and Bon…
TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
We love to hear from our listeners. Send us a message.
Among a growing cluster of Pittsburgh biotechs, you'll find BlueSphere Bio, an early-stage company discovering T-cell receptors to leverage agai…
BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko
We love to hear from our listeners. Send us a message.
SPECIAL EDITION: BoB@JPM
Elixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final episode in our special series recorde…
BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D.
We love to hear from our listeners. Send us a message.
SPECIAL EDITION: BOB@JPM
Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pi…
BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez
We love to hear from our listeners. Send us a message.
SPECIAL EDITION: BOB@JPM
Bolt Biotherapeutics CEO Randall Schatzman, Ph.D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech,…
BoB@JPM: Academia To Industry With Oncolytics' Matt Coffey, Ph.D.
We love to hear from our listeners. Send us a message.
SPECIAL EDITION: BoB@JPM
The JP Morgan Healthcare Conference is a target-rich environment for conversations with the leaders of up-and-coming bio…
BoB@JPM: Support Of A Blossoming Pipeline With Sangamo's Sandy Macrae, Ph.D.
We love to hear from our listeners. Send us a message.
SPECIAL EDITION: BoB@JPM
The Business of Biotech podcast took to the streets of San Francisco during the 41st Annual J.P. Morgan Healthcare Confe…
Building A Better COVID Vaccine With Ocugen's Shankar Musunuri, Ph.D.
We love to hear from our listeners. Send us a message.
Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder & CEO Shankar Musunuri, Ph.D. says yes, and his i…
Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed
We love to hear from our listeners. Send us a message.
Women In Biotech With Bill & Melinda Gates MRI's Piper Trelstad, Ph.D.
We love to hear from our listeners. Send us a message.
After more than 21 years leading process, product, and technical development efforts at Merck and Takeda, Piper Trelstad, Ph.D. joined the Bill …
Computational Drug Discovery With Gain Therapeutics' Matthias Alder
We love to hear from our listeners. Send us a message.
Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear explanation of how his company is applying compute …